Trial Profile
A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalic inclusion disorders
- Focus Therapeutic Use
- 19 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database
- 30 Jul 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 17 Jan 2013 Planned End Date changed from 1 Apr 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.